OXFORD, England, Jan. 10, 2024 /PRNewswire/ -- Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with ...

Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ...

Please provide your email address to receive an email when new articles are posted on . An artificial intelligence-guided algorithm to identify cardiac amyloidosis received a breakthrough device ...

AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...

Credit: Getty Images. NXC-201 is an autologous BCMA-targeted investigational chimeric antigen receptor T cell therapy. The Food and Drug Administration (FDA) has granted Orphan Drug designation to NXC ...